These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 17900250)

  • 1. Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation.
    Dai CY; Yu ML; Hsieh MY; Lee LP; Hou NJ; Huang JF; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY; Chuang WL
    Liver Int; 2007 Dec; 27(10):1364-70. PubMed ID: 17900250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
    Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
    Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B.
    Hann HW; Jonsson Funk ML; Rosenberg DM; Davis R
    J Gastroenterol Hepatol; 2005 Mar; 20(3):433-40. PubMed ID: 15740489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
    Jang JW; Bae SH; Choi JY; Kim CW; Han NI; Han JY; Choi SW; Yoon SK; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2006 Feb; 21(2):384-91. PubMed ID: 16509863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.